CA2624310C - Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide - Google Patents
Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide Download PDFInfo
- Publication number
- CA2624310C CA2624310C CA2624310A CA2624310A CA2624310C CA 2624310 C CA2624310 C CA 2624310C CA 2624310 A CA2624310 A CA 2624310A CA 2624310 A CA2624310 A CA 2624310A CA 2624310 C CA2624310 C CA 2624310C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- modification
- formula
- oxo
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 110
- 230000004048 modification Effects 0.000 claims description 88
- 238000012986 modification Methods 0.000 claims description 88
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 36
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 8
- 238000001228 spectrum Methods 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 6
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 39
- 239000002904 solvent Substances 0.000 description 18
- 239000012453 solvate Substances 0.000 description 17
- 150000001768 cations Chemical class 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 239000013543 active substance Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 10
- 238000002441 X-ray diffraction Methods 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000001413 far-infrared spectroscopy Methods 0.000 description 8
- 238000011321 prophylaxis Methods 0.000 description 8
- -1 for example Chemical compound 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 208000001435 Thromboembolism Diseases 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000002411 thermogravimetry Methods 0.000 description 5
- 238000001237 Raman spectrum Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 230000009424 thromboembolic effect Effects 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 238000001069 Raman spectroscopy Methods 0.000 description 2
- 206010038563 Reocclusion Diseases 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- BXEAAHIHFFIMIE-UHFFFAOYSA-N 3-chlorothiophene-2-carboxylic acid Chemical compound OC(=O)C=1SC=CC=1Cl BXEAAHIHFFIMIE-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102100035023 Carboxypeptidase B2 Human genes 0.000 description 1
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000004497 NIR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003705 antithrombocytic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 238000013194 cardioversion Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 101150084411 crn1 gene Proteins 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
- 229940049370 fibrinolysis inhibitor Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
Abstract
The present invention relates to a novel polymorphic form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl-methyl)-2-thiophenecarboxamide, processes for their preparation and medicaments comprising these forms.
Description
POLYMORPHIC FORM OF 5-CHLORO-N-(1(5S)-2-0X0-3-14-(3-0X0-4-MORPHOLINYL)-PHENYL1-1,3-0XAZOLIDIN-5-YL1-METHYL)-2-THIOPHENECARBOXAMIDE
The present invention relates to a novel polymorphic form and the amorphous form of 5-chloro-N-( {(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-phenyl]- 1 ,3-oxazolidin-5-y11-methyl)-2-thiophene-carboxamide, processes for their preparation and medicaments comprising these forms.
The compound 5-chloro-N-(1(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-y11-methyl)-2-thiophenecarboxamide is known from WO 01/47949 and WO 2004/060887 and corresponds to the formula (I):
0 _________________ /N
N N CI (I) The compound of the formula (1) is a low molecular weight, orally administrable inhibitor of blood clotting factor Xa, which might therefore be employed for the prophylaxis, secondary prophylaxis and/or treatment of various thromboembolic diseases (for this see WO 01/47919), in particular of myocardial infarct, angina pectoris (including unstable angina), reocclusions and restenoses after angioplasty or aortocoronary bypass, cerebral stroke, transitory ischemic attacks, peripheral arterial occlusive diseases, pulmonary embolisms or deep vein thromboses.
The compound of the formula (I) can be prepared as described in WO 01/47919 and WO
2004/060887. The compound of the formula (I) is obtained here in a crystal modification which is designated below as modification I. Modification I has a melting point of 230 C and a characteristic X-ray diffractogram, IR spectrum, Raman spectrum, FIR spectrum and NIR spectrum (Tab. 1-6, Fig. 1-6). It has now been found that modification 1 has a solubility lower by the factor 4 in comparison to the modification 11.
Surprisingly, two further modifications, a hydrate. an NMP solvate and an inclusion compound with THF of the compound of the formula (I) have been found. The compound of the formula (I) in the modification II melts at approximately 203 C and has a transition point of approximately 195 C, the compound of the formula (I) in the modification III has a transition point of approximately 127 C. The hydrate contains approximately 4% of water, the NMP
solvate contains 18.5% of N-methylpyrrolidone and the inclusion compound with THF approximately 5-7% of =
The present invention relates to a novel polymorphic form and the amorphous form of 5-chloro-N-( {(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-phenyl]- 1 ,3-oxazolidin-5-y11-methyl)-2-thiophene-carboxamide, processes for their preparation and medicaments comprising these forms.
The compound 5-chloro-N-(1(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-y11-methyl)-2-thiophenecarboxamide is known from WO 01/47949 and WO 2004/060887 and corresponds to the formula (I):
0 _________________ /N
N N CI (I) The compound of the formula (1) is a low molecular weight, orally administrable inhibitor of blood clotting factor Xa, which might therefore be employed for the prophylaxis, secondary prophylaxis and/or treatment of various thromboembolic diseases (for this see WO 01/47919), in particular of myocardial infarct, angina pectoris (including unstable angina), reocclusions and restenoses after angioplasty or aortocoronary bypass, cerebral stroke, transitory ischemic attacks, peripheral arterial occlusive diseases, pulmonary embolisms or deep vein thromboses.
The compound of the formula (I) can be prepared as described in WO 01/47919 and WO
2004/060887. The compound of the formula (I) is obtained here in a crystal modification which is designated below as modification I. Modification I has a melting point of 230 C and a characteristic X-ray diffractogram, IR spectrum, Raman spectrum, FIR spectrum and NIR spectrum (Tab. 1-6, Fig. 1-6). It has now been found that modification 1 has a solubility lower by the factor 4 in comparison to the modification 11.
Surprisingly, two further modifications, a hydrate. an NMP solvate and an inclusion compound with THF of the compound of the formula (I) have been found. The compound of the formula (I) in the modification II melts at approximately 203 C and has a transition point of approximately 195 C, the compound of the formula (I) in the modification III has a transition point of approximately 127 C. The hydrate contains approximately 4% of water, the NMP
solvate contains 18.5% of N-methylpyrrolidone and the inclusion compound with THF approximately 5-7% of =
tetrahydrofuran.
The present invention relates to the compound of the formula (I) in the modification II. By means of the use according to the invention of the compound of the formula (I) in the modification II, it is ensured that a higher solubility is achieved in comparison to the known modification.
Modification II of the compound of the formula (I), in comparison to modification I, modification III, the hydrate form, the NMP solvate and the inclusion compound with THF, has a clearly distinguishable X-ray diffractogram, IR spectrum, NIR spectrum, FIR spectrum and Raman spectrum (Fig. 2-6). The compound of the formula (I) in the modification II melts at 203 C and converts at approximately 195 C and is thus clearly distinguishable from modification I (melting point 230 C) and modification III (transition point approximately 127 C). In contrast to these solvent-free forms, the hydrate of the compound of the formula (I), the NMP solvate of the compound of the formula (I) and the inclusion compound with THF of the compound of the formula (I) show mass losses in thermogravimetric analysis (TGA) of 4%, 18.5% and 5-7% respectively (Fig. 1).
The compound of the formula (I) in the modification II shows peak maxima in the NIR
spectra at 4086, 4228, 4418, 4457, 4634, 4905, 5846, 5911, 6026, 6081 and 6582 cm*
It is generally known that crystalline polymorphic forms have a poorer water solubility than the amorphous form. This leads to a lower bioavailability in comparison to the amorphous form.
The present invention furthermore relates to the compound of the formula (I) in amorphous form. By means of the use according to the invention of the compound of the formula (I) in the amorphous form, it is ensured that maximum bioavailability is achieved.
The amorphous form of the compound of the formula (I) has a characteristic X-ray diffractogram, NIR spectrum, FIR spectrum and Raman spectrum (Fig. 8-12). The compound of the formula (I) in the amorphous form has a glass transition temperature of approximately 83 C (DSC, Fig. 7).
The present invention relates to the compound of the formula (I) in the modification II. By means of the use according to the invention of the compound of the formula (I) in the modification II, it is ensured that a higher solubility is achieved in comparison to the known modification.
Modification II of the compound of the formula (I), in comparison to modification I, modification III, the hydrate form, the NMP solvate and the inclusion compound with THF, has a clearly distinguishable X-ray diffractogram, IR spectrum, NIR spectrum, FIR spectrum and Raman spectrum (Fig. 2-6). The compound of the formula (I) in the modification II melts at 203 C and converts at approximately 195 C and is thus clearly distinguishable from modification I (melting point 230 C) and modification III (transition point approximately 127 C). In contrast to these solvent-free forms, the hydrate of the compound of the formula (I), the NMP solvate of the compound of the formula (I) and the inclusion compound with THF of the compound of the formula (I) show mass losses in thermogravimetric analysis (TGA) of 4%, 18.5% and 5-7% respectively (Fig. 1).
The compound of the formula (I) in the modification II shows peak maxima in the NIR
spectra at 4086, 4228, 4418, 4457, 4634, 4905, 5846, 5911, 6026, 6081 and 6582 cm*
It is generally known that crystalline polymorphic forms have a poorer water solubility than the amorphous form. This leads to a lower bioavailability in comparison to the amorphous form.
The present invention furthermore relates to the compound of the formula (I) in amorphous form. By means of the use according to the invention of the compound of the formula (I) in the amorphous form, it is ensured that maximum bioavailability is achieved.
The amorphous form of the compound of the formula (I) has a characteristic X-ray diffractogram, NIR spectrum, FIR spectrum and Raman spectrum (Fig. 8-12). The compound of the formula (I) in the amorphous form has a glass transition temperature of approximately 83 C (DSC, Fig. 7).
The compound of the formula (I) according to the invention in the modification II or in the amorphous form is employed in high purity in pharmaceutical formulations. For reasons of stability, a pharmaceutical formulation mainly contains the compound of the formula (I) in the modification II or in the amorphous form and no relatively large proportions of another form such as, for example, of another modification or of a solvate of the compound of the formula (I). Preferably, the medicament contains more than 90 percent by weight, particularly preferably more than 95 percent by weight of the compound of the formula (I) in the modification II or in the amorphous form based on the total amount of the compound of the formula (I) contained.
The compounds of the formula (I) in the modification II or in the amorphous form might be used for the treatment and/or prophylaxis of diseases, preferably of thromboembolic diseases and/or thromboembolic complications.
The "thromboembolic diseases" within the meaning of the present invention in particular include diseases such as myocardial infarct with ST segment elevation (STEMI) and without ST segment elevation (non-STEMI), stable angina pectoris, unstable angina pectoris, reocclusions and restenoses after coronary interventions such as angioplasty or aortocoronary bypass, peripheral arterial occlusive diseases, pulmonary embolisms, deep vein thromboses and renal vein thromboses, transitory ischemic attacks, and thrombotic and thromboembolic cerebral stroke.
The compound according to the invention might also be suitable for the prevention and treatment of cardiogenic thromboembolisms, such as, for example, cerebral ischemias, stroke and systemic thromboembolisms and ischemias in patients with acute, intermittent or persistent cardiac anthythmias, such as, for example, atrial fibrillation, and those who are subject to cardioversion, furthermore in the case of patients with heart valve diseases or with artificial heart valves. Moreover, the compound according to the invention might be suitable for the treatment of disseminated intravasal clotting (DIC).
Thromboembolic complications furthermore occur in microangiopathic hemolytic anemias, extracorporeal blood circulations, such as hemodialysis, and heart valve prostheses.
- 3a -Moreover, the compound according to the invention might also be suitable for the prophylaxis and/or treatment of atherosclerotic vascular diseases and inflammatory diseases such as rheumatic diseases of the locomotor system, moreover might also be useful for the prophylaxis and/or treatment of Alzheimer's disease. Moreover, the compound according to the invention might also be employed for the inhibition of tumor growth and of metastasis formation, in microangiopathies, age-related macular degeneration, diabetic retinopathy, diabetic nephropathy and other microvascular diseases, and for the prevention and treatment of thromboembolic complications, such as, for example, venous thromboembolisms, in tumor patients, in particular those who are subjected to relatively large surgical interventions or chemo- or radiotherapy.
The compound according to the invention might also moreover be employed for the prevention of coagulation ex vivo, e.g. for the preservation of blood and plasma products, for the cleaning/pretreatment of catheters and other medical aids and equipment, for the coating of artificial surfaces of medical aids and equipment employed in vivo or ex vivo or in 1 5 biological samples which contain factor Xa.
The compound according to the invention might also be used for the treatment and/or prophylaxis of diseases, in particular of the aforementioned diseases.
The compound according to the invention might also be used for the production of a medicament for the treatment and/or prophylaxis of diseases, in particular of the aforementioned diseases.
The present invention furthermore relates to medicaments comprising the compound according to the invention and one or more other active substances, which might be used for the treatment and/or prophylaxis of the aforementioned diseases. Suitable combination active substances which may be mentioned by way of example and preferably are:
= lipid-lowering agents, in particular HMG-CoA-(3-hydroxy-3-methylglutaryl-coenzyme A)-reductase inhibitors;
= coronary therapeutics/vasodilators, in particular ACE (angiotensin converting enzyme) inhibitors;
All (angiotensin II) receptor antagonists; P-adrenoceptor antagonists; alpha-l-adrenoceptor antagonists; diuretics; calcium channel blockers; substances which bring about an increase in cyclic guanosine monophosphate (cGMP), such as, for example, stimulators of soluble guanylate cyclase;
= plasminogen activators (thrombolytics/fibrinolytics) and thrombolysis/fibrinolysis-increasing compounds such as inhibitors of the plasminogen activator inhibitor (PAI
inhibitors) or inhibitors of the thrombin-activated fibrinolysis inhibitor (TAFI inhibitors);
= substances having anticoagulatory activity (anticoagulants);
= substances inhibiting platelet aggregation (platelet aggregation inhibitors, thrombocyte aggregation inhibitors);
= and fibrinogen receptor antagonists (glycoproteip Ilb/Illa antagonists).
The present invention further relates to medicaments which contain the compound according to the invention, customarily together with one or more inert, nontoxic, pharmaceutically suitable excipients, and their possible use for the aforementioned purposes.
The compound according to the invention can act systemically and/or locally.
For this purpose, they can be administered in a suitable manner, such as, for example, orally, parenterally, pulmonarily, BHC 05 1 117-Foreign countries nasally, sublingually, lingually, buccally, rectally, dermally, transdermally, conjunctivally, otically or as an implant or stent.
For these administration routes, the compound according to the invention can be administered in suitable administration forms.
For oral administration, administration forms functioning according to the prior art, releasing the compound according to the invention rapidly and/or in modified form, which contain the compound of the formula (I) in the modification 11 or in the amorphous form, such as, for example, tablets (noncoated or coated tablets, for example with enteric coatings or coatings which dissolve with a delay or are insoluble, which control the release of the compound according to the invention), tablets disintegrating rapidly in the oral cavity or films/wafers, films/lyophilizates, capsules (for example hard or soft gelatin capsules), coated tablets, granules, pellets, powders, suspensions or aerosols are suitable.
Parenteral administration can take place with circumvention of an absorption step (e.g. intravenously, intraarterially, intracardially, intraspinally or intralumbarly) or with intervention of an absorption (e.g.
intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally). For parenteral administration, suitable administration forms are, inter alia, injection and infusion preparations in the form of suspensions, lyophilizates or sterile powders.
For the other administration routes, for example, inhalation pharmaceutical forms (inter alia powder inhalers, nebulizers), tablets to be administered lingually, sublingually or buccally, films/wafers or capsules, suppositories, ear or eye preparations, vaginal capsules, aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (e.g. patches), milk, pastes, foams, dusting powders, implants or stents are suitable.
Oral or parenteral administration is preferred, in particular oral administration.
The compound according to the invention can be converted to the administration forms mentioned.
This can take place in a manner known per se by mixing with inert, nontoxic, pharmaceutically suitable excipients. These excipients include, inter alia, vehicles (for example microcrystalline cellulose, lactose, mannitol), solvents (e.g. liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecylsulfate, polyoxysorbitan oleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers (e.g.
antioxidants such as, for example, ascorbic acid), colorants (e.g. inorganic pigments such as, for example, iron oxides) and taste and/or odor corrigents.
In general, it has proven advantageous in the case of parenteral administration to administer amounts of approximately 0.001 to 1 mg/kg, preferably approximately 0.01 to 0.5 mg/kg of body weight to BHC 05 1117-Foreign countries achieve effective results. In the case of oral administration, the dose is approximately 0.01 to 100 mg/kg, preferably approximately 0.01 to 20 mg/kg and very particularly preferably 0.1 to 10 mg/kg of body weight.
In spite of this, it may optionally be necessary to depart from the amounts mentioned, namely depending on body weight, route of administration, individual behavior toward the medicament, type of preparation and time or interval at which administration takes place. Thus in some cases it may be adequate to manage with less than the aforementioned minimum amount, whereas in other cases the upper limit mentioned must be exceeded. In the case of the administration of relatively large amounts, it may be advisable to divide these into a number of individual doses over the course of the day.
The invention further relates to a process for the preparation of the compound of the formula (I) in the modification II, by dissolving the compound of the formula (I) in the modification I in an inert solvent and precipitating the active substance by addition of a precipitating agent at a temperature between 0 C and 80 C, preferably from 20 to 25 C. The precipitate is isolated and dried. The compound of the formula (I) is thus obtained in the modification II.
The invention likewise relates to a process for the preparation of the compound of the formula (1) in the modification II, by dissolving the compound of the formula (I) in the modification I in an inert solvent and storing it, preferably at elevated temperature, in particular at a temperature of 30 C up to the reflux temperature of the solvent, until the complete evaporation of the solvent and crystallization of the active substance. The compound of the formula (I) is thus obtained in the modification II.
The invention likewise relates to a process for the preparation of the compound of the formula (I) in the modification II, by suspending the compound of the formula (I) in the amorphous form in an anhydrous inert solvent and stirring or shaking it until achieving the desired degree of conversion, in particular until quantitative conversion, to the modification II. The crystallizate obtained is isolated and dried. The compound of the formula (I) is thus obtained in the modification II.
Suitable inert solvents are lower alcohols such as, for example, methanol, ethanol, n-propanol, iso-propanol, n-butanol, sec-butanol, isobutanol, 1-pentanol, or ketones such as acetone, or alkanes such as n-pentane, cyclopentane, n-hexane, cyclohexane, or tetrahydrofuran, or acetonitrile, or toluene, or ethyl acetate, or 1,4-dioxane, or mixtures of the solvents mentioned, or mixtures of the solvents mentioned with water. Acetone, tetrahydrofuran, 1-pentanol or mixtures of the solvents mentioned are preferred. Suitable precipitating agents are inert, anhydrous solvents, in which the active substance is poorly soluble, such as, for example, n-heptane, cyclohexane or toluene. n-Heptane is preferred.
BHC 05 I 117-Foreign countries Preferably, the compound of the formula (I) is prepared in the modification II, by dissolving the compound of the formula (I) in the modification I in acetone or tetrahydrofuran and precipitating the active substance by addition of n-heptane at a temperature between 0 and 80 C, preferably at a temperature from 20 to 25 C. The precipitate is isolated and dried. The compound of the formula (1) is thus obtained in the modification II.
Likewise preferably, the compound of the formula (I) is prepared in the modification II, by dissolving the compound of the formula (1) in the modification 1 in 1,4-dioxane and storing at elevated temperature, in particular at a temperature from 30 C up to the reflux temperature of the solvent, for example 50 C, until the complete evaporation of the solvent and crystallization of the active substance. The compound of the formula (I) is thus obtained in the modification II.
Likewise preferably, the compound of the formula (I) is prepared in the modification II, by suspending the compound of the formula (1) in the amorphous form in an inert anhydrous solvent and stirring or shaking at a temperature of 20 to 25 C until achieving the desired degree of conversion to the modification 11. The crystallizate obtained is isolated and dried. The compound of the formula (I) is thus obtained in the modification II.
The invention further relates to a process for the preparation of the compound of the formula (1) in the amorphous form, in which the compound of the formula (1) in a crystalline form is fused and subsequently rapidly cooled. The compound of the formula (I) is thus obtained in the amorphous form.
Preferably, the compound of the formula (I) is prepared in the amorphous form, by fusing the compound of the formula (I) in a crystalline form at a temperature of at least 230 C, in particular at a temperature of 240 to 250 C, and subsequently rapidly cooling it. The compound of the formula (I) is thus obtained in the amorphous form.
Of the crystalline forms modification 1, II and III, preferably modification I
or II, are employed here, in particular modification I.
By means of rapid cooling, the temperature of the compound (I) is preferably brought to or close to room temperature, for example to a temperature of approximately 15 to 30 C, in particular of approximately 20 to 25 C. The rapid cooling is preferably carried out in the course of a few seconds, for example in the course of approximately 5 seconds. Shock cooling is preferably employed for rapid cooling.
The compound of the formula (I) in the modification III can be prepared by dissolving the compound of the formula (I) in the modification I in an inert solvent, for example acetone. The = BHC 05 1117-Foreign countries solution is treated with water and allowed to stand at room temperature until the solvent has completely evaporated. The compound of the formula (I) is thus obtained in the modification III.
The hydrate of the compound of the formula (I) can be prepared by dissolving the compound of the formula (I) in the modification I in ethanol:water (1:1). The solution is a stored at a temperature of approximately ¨20 C until the solvent has evaporated. The hydrate of the compound of the formula (I) is thus obtained.
The NMP solvate of the compound of the formula (I) can be prepared by suspending the compound of the formula (I) in the modification 1 in 1-methyl-2-pyrrolidone and stirring at room temperature.
After 2 days, the suspension is filtered and the product is dried. The NMP
solvate of the compound of the formula (I) with an NMP content of 18.5 percent by weight is thus obtained.
The inclusion compound with THF of the compound of the formula (I) can be prepared by dissolving the compound of the formula (I) in the modification I in tetrahydrofuran. The solution is stored at room temperature until the solvent has evaporated. The inclusion compound with THF of the compound of the formula (I) is thus obtained.
The percentages in the following tests and examples, if not stated otherwise, are percentages by weight; parts are parts by weight. Solvent ratios, dilution ratios and concentration data of liquid/liquid solutions in each case relate to the volume.
BHC 05 1 117-Foreign countries Working examples The thermograms were obtained using a DSC 7 or Pyris-1 differential scanning calorimeter and TGA 7 thermogravimetric analyzer from Perkin-Elmer. The X-ray diffractograms were recorded in a Stoe transmission diffractometer. The IR, FIR, NIR and Raman spectra were recorded using IFS
66v Fourier IR (IR, FIR), IFS 28/N (NIR) and RFS 100 (Raman) spectrometers from Bruker.
Example 1: 5-Chloro-N-(1(5S)-2-oxo-3-14-(3-oxo-4-morpholinyfi-pheny11-1,3-oxazolidin-5-y11-methyl)-2-thiophenecarboxamide in the modification I
The preparation of the modification I of the title compound is described in WO
01/47949 and WO
2004/060887.
Example 2: Preparation of 5-chloro-N-(1(5S)-2-oxo-3-14-(3-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification II
Example 2.1 208 g of chlorothiophenecarboxylic acid were suspended in 1100 ml of toluene and heated to 75 to 80 C. 112 ml of thionyl chloride were added dropwise at this temperature in the course of 2 h. The resulting reaction solution was stirred for a further 2 h until the end of evolution of gas. In the course of this, the internal temperature was increased to 100-110 C in 5 steps. The mixture was cooled and the solution of the acid chloride was concentrated on a rotary evaporator.
350 g of oxamine hydrochloride were suspended in 2450 ml of NMP, treated with 385 ml of triethylamine and stirred for 15 min. The mixture was cooled to 10 C, treated with the solution of the acid chloride and 70 ml of toluene and stirred. 350 ml of tap water were added to the suspension and it was heated to 82 C. After filtration, the active substance was precipitated using 3.5 1 of water and the mixture was subsequently stirred for 2 h. Drying at 70 C in vacuo.
Example 2.2 About 200 mg of 5-chloro-N-({(5S)-2-oxo-314-(3-oxo-4-morpholiny1)-phenyl]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were dissolved hot in about 80 ml of tetrahydrofuran. The solution was filtered and divided in half. One half was treated at room temperature with n-heptane until the active substance precipitated. The residue was filtered off and dried at room temperature. It was investigated by X-ray diffractometry and corresponded to the title compound in the modification II.
= BHC 05 1117-Foreign countries Example 2.3 About 200 mg of 5-chloro-N-({(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-pheny1]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were dissolved hot in about 40 ml of I -pentanol. The solution was filtered and divided in half. One half was treated with n-heptane until the active substance precipitated. The residue was filtered off and dried at room temperature. It was investigated by X-ray diffractometry and corresponded to the title compound in the modification II.
Example 2.4 About 200 mg of 5-chloro-N-({(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were dissolved hot in about 40 ml of 1,4-dioxane. The solution was filtered and divided in half. One half was stored at 50 C in a drying oven until the solvent had evaporated. The residue was investigated by X-ray diffractometry and corresponded to the title compound in the modification 11.
Example 2.5 About 50 mg of 5-chloro-N-M5S)-2-oxo-344-(3-oxo-4-morpholiny1)-phenyl]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the amorphous form, prepared by fusing on a Kofler heating bench at about 240 C and subsequent shock cooling to room temperature, were suspended in about 2 ml of ethanol and stirred at 25 C for 0.5 h. The crystallizate was isolated and dried. The residue was investigated by X-ray diffractometry and corresponded to the title compound in the modification II.
Example 2.6 About 100 mg of 5-chloro-N-({(55)-2-oxo-3-[4-(3-oxo-4-morpholiny1)-phenyl]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were dissolved hot in about 50 ml of acetone. The solution was filtered and treated with n-heptane in an ice bath until the active substance precipitated. The residue was filtered off and dried at room temperature. It was investigated by X-ray diffractometry and corresponded to the title compound in the modification II.
Example 3: Preparation of 5-chloro-N-W5S)-2-oxo-3-1443-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-y1I-methyl)-2-thiophenecarboxamide in the modification III
About 120 mg of 5-chloro-N-({(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-pheny1]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were dissolved hot in about 50 ml of acetone. The solution was filtered, treated with about 50 ml of water and allowed to stand at room temperature until the solvent had evaporated. The residue was investigated thermoanalytically and BHC 05 1 I 17-Foreign countries corresponded to the title compound in the modification III.
Example 4: Preparation of the hydrate of 5-chloro-N-M5S)-2-oxo-3-14-(3-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide About 400 mg of 5-chloro-N-( {(5S)-2-oxo-3-[4-(3-oxo-4-morpholiny1)-pheny1]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were dissolved hot in about 60 ml of ethanol:water (1:1) and filtered. A part of the solution was stored in a freezer at a temperature of approximately ¨20 C until the solvent had evaporated. The residue corresponded to the hydrate of the title compound.
Example 5: Preparation of the NMP solvate of 5-chloro-N-({(5S)-2-oxo-3-14-(3-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide About 3.5 g of 5-chloro-N-(1(5,9-2-oxo-344-(3-oxo-4-morpholiny1)-phenyl]-1,3-oxazolidin-5-y11-methyl)-2-thiophenecarboxamide in the modification I were suspended in 10 ml of 1-methy1-2-pyrrolidone and stirred at room temperature. After a few hours, about 20 ml of NMP were additionally added. After two days, the suspension was filtered off with suction and the residue was dried at room temperature. The residue was investigated thermoanalytically and corresponded to the NMP solvate of the title compound having an NMP content of 18.5 percent by weight.
Example 6: Preparation of the inclusion compound with THF of 5-chloro-N-(1(5S)-2-oxo-3-14-(3-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide About 400 mg of 5-chloro-N-({(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-pheny1]-1,3-oxazolidin-5-y1l-methy1)-2-thiophenecarboxamide in the modification I were dissolved hot in about 50 ml of tetrahydrofuran and filtered. A part of the solution was stored at room temperature until the solvent had evaporated. The residue was investigated thermoanalytically and corresponded to the inclusion compound with THF of the title compound.
Tab. 1: Differential scanning calorimetry and thermogravimetry Modifi- Modifi- Modifi- Hydrate NMP ESV
cation I cation II cation III solvate toluene Melting point [ C] 230 203 Transition point [ C] ca. 192 ca. 127 Mass loss [% by wt.] 0.1 0.1 <0.5 ca. 4 18.5 5-7 BHC 05 1117-Foreign countries , Tab. 2: X-ray diffractometry iReflections Modifi- Modifi- Modifi- Hydrate NMP ESV
with cation I cation II cation 111 [2 theta]
solvate THF
[2 theta] [2 theta] [2 theta] [2 theta] [2 theta]
8.9 12.8 11.7 3.6 4.8 9.0 12.0 17.7 16.5 14.3 5.8 12.0 14.3 18.1 17.5 16.4 7.3 14.3 16.5 18.4 19.1 16.6 10.9 14.7 17.4 19.0 19.6 17.5 14.5 16.5 18.1 19.9 19.8 19.3 15.2 16.8 19.5 20.8 23.1 19.6 15.7 17.5 19.9 21.6 23.2 19.9 16.0 19.6 21.7 22.1 23.8 20.2 17.6 19.9 22.5 22.9 24.3 21.7 17.9 21.7 23.4 24.1 28.1 22.5 20.0 22.5 24.1 26.1 28.2 24.2 20.6 23.4 24.5 26.4 31.2 25.6 21.3 24.5 24.7 26.6 25.8 21.8 24.7 25.6 27.2 28.8 22.3 25.2 26.4 27.5 29.5 22.7 25.6 26.7 28.8 31.8 23.1 26.4 30.0 29.8 32.7 23.3 26.7 30.1 31.0 23.5 28.7 31.8 31.6 24.0 30.1 32.9 24.7 31.0 24.9 31.8 25.2 26.0 26.5 26.9 28.0 28.8 29.2 29.5 29.8 BHC 05 1 117-Foreign countries Tab. 3: IR spectroscopy Peak maxima Modification Modification Modification Hydrate NMP
II II III [cm-I] solvate [cm-1] [cm-1 [cm-1] [cm4]
BHC 05 1117-Foreign coucnktriOes2624310 2008-04-01 Peak maxima Modification Modification Modification Hydrate NMP
II II III [cm-11 solvate [aril [cm-'1 [cm-11 [cm'l I
Tab. 4: Raman spectroscopy Peak maxima Modifi- Modifi- Modifi- Hydrate NMP
cation I cation II cation III [crn1 solvate [cm} [cm] [cm-1] [cm-l]
= BHC 05 1 117-Foreign countries Peak maxima Modifi- Modifi- Modifi- Hydrate NMP
cation I cation 11 cation III [cm']
solvate [cm-I] [cm] [cm-1 [cm-I]
BHC 05 1 117-Foreign countries Tab. 5: FIR spectroscopy Peak maxima Modifi- Modifi- Hydrate NMP solvate cation I cation II [cm'] [cm']
[cm1] [cm-l]
. BHC 05 1117-Foreign countries Tab. 6: NIR spectroscopy Peak maxima Modifi- Modifi- Modifi- Hydrate NMP
cation 1 cation I cation I
[cm-1 solvate [cm'} [cm'] [cm-1 [cm-1]
Example 7: Preparation of 5-chloro-N-(1(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-phenyll-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in amorphous form Example 7.1 About 50 mg of 5-chloro-N-(1(55)-2-oxo-344-(3-oxo-4-morpholiny1)-phenyl]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification 1 were fused on a Kofler heating bench at about 240 C and subsequently brought to room temperature by shock cooling. The active substance was investigated by X-ray diffractometry and was present in the amorphous form.
BHC 05 1117-Foreign countries Example 7.2 About 3 g of 5-chloro-N-({(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-phenyl]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were fused in a drying oven at about 250 C
and subsequently brought to room temperature by shock cooling. The active compound was investigated by X-ray diffractometry and was present in the amorphous form.
Tab. 7: Differential scanning calorimetry and thermogravimetry (amorphous form) Glass transition temperature: about 83 C
Tab. 8: Spectroscopy (amorphous form) Peak maxima IR Raman FIR NIR
[cm-1] [cm-1] [cm-1] [cm-1]
BHC 05 1 117-Foreign countries CA 02624310 2008-04-01 Peak maxima IR Raman FIR NIR
[cm-11 [cm -11 [cm-1] [cm-1]
The compounds of the formula (I) in the modification II or in the amorphous form might be used for the treatment and/or prophylaxis of diseases, preferably of thromboembolic diseases and/or thromboembolic complications.
The "thromboembolic diseases" within the meaning of the present invention in particular include diseases such as myocardial infarct with ST segment elevation (STEMI) and without ST segment elevation (non-STEMI), stable angina pectoris, unstable angina pectoris, reocclusions and restenoses after coronary interventions such as angioplasty or aortocoronary bypass, peripheral arterial occlusive diseases, pulmonary embolisms, deep vein thromboses and renal vein thromboses, transitory ischemic attacks, and thrombotic and thromboembolic cerebral stroke.
The compound according to the invention might also be suitable for the prevention and treatment of cardiogenic thromboembolisms, such as, for example, cerebral ischemias, stroke and systemic thromboembolisms and ischemias in patients with acute, intermittent or persistent cardiac anthythmias, such as, for example, atrial fibrillation, and those who are subject to cardioversion, furthermore in the case of patients with heart valve diseases or with artificial heart valves. Moreover, the compound according to the invention might be suitable for the treatment of disseminated intravasal clotting (DIC).
Thromboembolic complications furthermore occur in microangiopathic hemolytic anemias, extracorporeal blood circulations, such as hemodialysis, and heart valve prostheses.
- 3a -Moreover, the compound according to the invention might also be suitable for the prophylaxis and/or treatment of atherosclerotic vascular diseases and inflammatory diseases such as rheumatic diseases of the locomotor system, moreover might also be useful for the prophylaxis and/or treatment of Alzheimer's disease. Moreover, the compound according to the invention might also be employed for the inhibition of tumor growth and of metastasis formation, in microangiopathies, age-related macular degeneration, diabetic retinopathy, diabetic nephropathy and other microvascular diseases, and for the prevention and treatment of thromboembolic complications, such as, for example, venous thromboembolisms, in tumor patients, in particular those who are subjected to relatively large surgical interventions or chemo- or radiotherapy.
The compound according to the invention might also moreover be employed for the prevention of coagulation ex vivo, e.g. for the preservation of blood and plasma products, for the cleaning/pretreatment of catheters and other medical aids and equipment, for the coating of artificial surfaces of medical aids and equipment employed in vivo or ex vivo or in 1 5 biological samples which contain factor Xa.
The compound according to the invention might also be used for the treatment and/or prophylaxis of diseases, in particular of the aforementioned diseases.
The compound according to the invention might also be used for the production of a medicament for the treatment and/or prophylaxis of diseases, in particular of the aforementioned diseases.
The present invention furthermore relates to medicaments comprising the compound according to the invention and one or more other active substances, which might be used for the treatment and/or prophylaxis of the aforementioned diseases. Suitable combination active substances which may be mentioned by way of example and preferably are:
= lipid-lowering agents, in particular HMG-CoA-(3-hydroxy-3-methylglutaryl-coenzyme A)-reductase inhibitors;
= coronary therapeutics/vasodilators, in particular ACE (angiotensin converting enzyme) inhibitors;
All (angiotensin II) receptor antagonists; P-adrenoceptor antagonists; alpha-l-adrenoceptor antagonists; diuretics; calcium channel blockers; substances which bring about an increase in cyclic guanosine monophosphate (cGMP), such as, for example, stimulators of soluble guanylate cyclase;
= plasminogen activators (thrombolytics/fibrinolytics) and thrombolysis/fibrinolysis-increasing compounds such as inhibitors of the plasminogen activator inhibitor (PAI
inhibitors) or inhibitors of the thrombin-activated fibrinolysis inhibitor (TAFI inhibitors);
= substances having anticoagulatory activity (anticoagulants);
= substances inhibiting platelet aggregation (platelet aggregation inhibitors, thrombocyte aggregation inhibitors);
= and fibrinogen receptor antagonists (glycoproteip Ilb/Illa antagonists).
The present invention further relates to medicaments which contain the compound according to the invention, customarily together with one or more inert, nontoxic, pharmaceutically suitable excipients, and their possible use for the aforementioned purposes.
The compound according to the invention can act systemically and/or locally.
For this purpose, they can be administered in a suitable manner, such as, for example, orally, parenterally, pulmonarily, BHC 05 1 117-Foreign countries nasally, sublingually, lingually, buccally, rectally, dermally, transdermally, conjunctivally, otically or as an implant or stent.
For these administration routes, the compound according to the invention can be administered in suitable administration forms.
For oral administration, administration forms functioning according to the prior art, releasing the compound according to the invention rapidly and/or in modified form, which contain the compound of the formula (I) in the modification 11 or in the amorphous form, such as, for example, tablets (noncoated or coated tablets, for example with enteric coatings or coatings which dissolve with a delay or are insoluble, which control the release of the compound according to the invention), tablets disintegrating rapidly in the oral cavity or films/wafers, films/lyophilizates, capsules (for example hard or soft gelatin capsules), coated tablets, granules, pellets, powders, suspensions or aerosols are suitable.
Parenteral administration can take place with circumvention of an absorption step (e.g. intravenously, intraarterially, intracardially, intraspinally or intralumbarly) or with intervention of an absorption (e.g.
intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally). For parenteral administration, suitable administration forms are, inter alia, injection and infusion preparations in the form of suspensions, lyophilizates or sterile powders.
For the other administration routes, for example, inhalation pharmaceutical forms (inter alia powder inhalers, nebulizers), tablets to be administered lingually, sublingually or buccally, films/wafers or capsules, suppositories, ear or eye preparations, vaginal capsules, aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (e.g. patches), milk, pastes, foams, dusting powders, implants or stents are suitable.
Oral or parenteral administration is preferred, in particular oral administration.
The compound according to the invention can be converted to the administration forms mentioned.
This can take place in a manner known per se by mixing with inert, nontoxic, pharmaceutically suitable excipients. These excipients include, inter alia, vehicles (for example microcrystalline cellulose, lactose, mannitol), solvents (e.g. liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecylsulfate, polyoxysorbitan oleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers (e.g.
antioxidants such as, for example, ascorbic acid), colorants (e.g. inorganic pigments such as, for example, iron oxides) and taste and/or odor corrigents.
In general, it has proven advantageous in the case of parenteral administration to administer amounts of approximately 0.001 to 1 mg/kg, preferably approximately 0.01 to 0.5 mg/kg of body weight to BHC 05 1117-Foreign countries achieve effective results. In the case of oral administration, the dose is approximately 0.01 to 100 mg/kg, preferably approximately 0.01 to 20 mg/kg and very particularly preferably 0.1 to 10 mg/kg of body weight.
In spite of this, it may optionally be necessary to depart from the amounts mentioned, namely depending on body weight, route of administration, individual behavior toward the medicament, type of preparation and time or interval at which administration takes place. Thus in some cases it may be adequate to manage with less than the aforementioned minimum amount, whereas in other cases the upper limit mentioned must be exceeded. In the case of the administration of relatively large amounts, it may be advisable to divide these into a number of individual doses over the course of the day.
The invention further relates to a process for the preparation of the compound of the formula (I) in the modification II, by dissolving the compound of the formula (I) in the modification I in an inert solvent and precipitating the active substance by addition of a precipitating agent at a temperature between 0 C and 80 C, preferably from 20 to 25 C. The precipitate is isolated and dried. The compound of the formula (I) is thus obtained in the modification II.
The invention likewise relates to a process for the preparation of the compound of the formula (1) in the modification II, by dissolving the compound of the formula (I) in the modification I in an inert solvent and storing it, preferably at elevated temperature, in particular at a temperature of 30 C up to the reflux temperature of the solvent, until the complete evaporation of the solvent and crystallization of the active substance. The compound of the formula (I) is thus obtained in the modification II.
The invention likewise relates to a process for the preparation of the compound of the formula (I) in the modification II, by suspending the compound of the formula (I) in the amorphous form in an anhydrous inert solvent and stirring or shaking it until achieving the desired degree of conversion, in particular until quantitative conversion, to the modification II. The crystallizate obtained is isolated and dried. The compound of the formula (I) is thus obtained in the modification II.
Suitable inert solvents are lower alcohols such as, for example, methanol, ethanol, n-propanol, iso-propanol, n-butanol, sec-butanol, isobutanol, 1-pentanol, or ketones such as acetone, or alkanes such as n-pentane, cyclopentane, n-hexane, cyclohexane, or tetrahydrofuran, or acetonitrile, or toluene, or ethyl acetate, or 1,4-dioxane, or mixtures of the solvents mentioned, or mixtures of the solvents mentioned with water. Acetone, tetrahydrofuran, 1-pentanol or mixtures of the solvents mentioned are preferred. Suitable precipitating agents are inert, anhydrous solvents, in which the active substance is poorly soluble, such as, for example, n-heptane, cyclohexane or toluene. n-Heptane is preferred.
BHC 05 I 117-Foreign countries Preferably, the compound of the formula (I) is prepared in the modification II, by dissolving the compound of the formula (I) in the modification I in acetone or tetrahydrofuran and precipitating the active substance by addition of n-heptane at a temperature between 0 and 80 C, preferably at a temperature from 20 to 25 C. The precipitate is isolated and dried. The compound of the formula (1) is thus obtained in the modification II.
Likewise preferably, the compound of the formula (I) is prepared in the modification II, by dissolving the compound of the formula (1) in the modification 1 in 1,4-dioxane and storing at elevated temperature, in particular at a temperature from 30 C up to the reflux temperature of the solvent, for example 50 C, until the complete evaporation of the solvent and crystallization of the active substance. The compound of the formula (I) is thus obtained in the modification II.
Likewise preferably, the compound of the formula (I) is prepared in the modification II, by suspending the compound of the formula (1) in the amorphous form in an inert anhydrous solvent and stirring or shaking at a temperature of 20 to 25 C until achieving the desired degree of conversion to the modification 11. The crystallizate obtained is isolated and dried. The compound of the formula (I) is thus obtained in the modification II.
The invention further relates to a process for the preparation of the compound of the formula (1) in the amorphous form, in which the compound of the formula (1) in a crystalline form is fused and subsequently rapidly cooled. The compound of the formula (I) is thus obtained in the amorphous form.
Preferably, the compound of the formula (I) is prepared in the amorphous form, by fusing the compound of the formula (I) in a crystalline form at a temperature of at least 230 C, in particular at a temperature of 240 to 250 C, and subsequently rapidly cooling it. The compound of the formula (I) is thus obtained in the amorphous form.
Of the crystalline forms modification 1, II and III, preferably modification I
or II, are employed here, in particular modification I.
By means of rapid cooling, the temperature of the compound (I) is preferably brought to or close to room temperature, for example to a temperature of approximately 15 to 30 C, in particular of approximately 20 to 25 C. The rapid cooling is preferably carried out in the course of a few seconds, for example in the course of approximately 5 seconds. Shock cooling is preferably employed for rapid cooling.
The compound of the formula (I) in the modification III can be prepared by dissolving the compound of the formula (I) in the modification I in an inert solvent, for example acetone. The = BHC 05 1117-Foreign countries solution is treated with water and allowed to stand at room temperature until the solvent has completely evaporated. The compound of the formula (I) is thus obtained in the modification III.
The hydrate of the compound of the formula (I) can be prepared by dissolving the compound of the formula (I) in the modification I in ethanol:water (1:1). The solution is a stored at a temperature of approximately ¨20 C until the solvent has evaporated. The hydrate of the compound of the formula (I) is thus obtained.
The NMP solvate of the compound of the formula (I) can be prepared by suspending the compound of the formula (I) in the modification 1 in 1-methyl-2-pyrrolidone and stirring at room temperature.
After 2 days, the suspension is filtered and the product is dried. The NMP
solvate of the compound of the formula (I) with an NMP content of 18.5 percent by weight is thus obtained.
The inclusion compound with THF of the compound of the formula (I) can be prepared by dissolving the compound of the formula (I) in the modification I in tetrahydrofuran. The solution is stored at room temperature until the solvent has evaporated. The inclusion compound with THF of the compound of the formula (I) is thus obtained.
The percentages in the following tests and examples, if not stated otherwise, are percentages by weight; parts are parts by weight. Solvent ratios, dilution ratios and concentration data of liquid/liquid solutions in each case relate to the volume.
BHC 05 1 117-Foreign countries Working examples The thermograms were obtained using a DSC 7 or Pyris-1 differential scanning calorimeter and TGA 7 thermogravimetric analyzer from Perkin-Elmer. The X-ray diffractograms were recorded in a Stoe transmission diffractometer. The IR, FIR, NIR and Raman spectra were recorded using IFS
66v Fourier IR (IR, FIR), IFS 28/N (NIR) and RFS 100 (Raman) spectrometers from Bruker.
Example 1: 5-Chloro-N-(1(5S)-2-oxo-3-14-(3-oxo-4-morpholinyfi-pheny11-1,3-oxazolidin-5-y11-methyl)-2-thiophenecarboxamide in the modification I
The preparation of the modification I of the title compound is described in WO
01/47949 and WO
2004/060887.
Example 2: Preparation of 5-chloro-N-(1(5S)-2-oxo-3-14-(3-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification II
Example 2.1 208 g of chlorothiophenecarboxylic acid were suspended in 1100 ml of toluene and heated to 75 to 80 C. 112 ml of thionyl chloride were added dropwise at this temperature in the course of 2 h. The resulting reaction solution was stirred for a further 2 h until the end of evolution of gas. In the course of this, the internal temperature was increased to 100-110 C in 5 steps. The mixture was cooled and the solution of the acid chloride was concentrated on a rotary evaporator.
350 g of oxamine hydrochloride were suspended in 2450 ml of NMP, treated with 385 ml of triethylamine and stirred for 15 min. The mixture was cooled to 10 C, treated with the solution of the acid chloride and 70 ml of toluene and stirred. 350 ml of tap water were added to the suspension and it was heated to 82 C. After filtration, the active substance was precipitated using 3.5 1 of water and the mixture was subsequently stirred for 2 h. Drying at 70 C in vacuo.
Example 2.2 About 200 mg of 5-chloro-N-({(5S)-2-oxo-314-(3-oxo-4-morpholiny1)-phenyl]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were dissolved hot in about 80 ml of tetrahydrofuran. The solution was filtered and divided in half. One half was treated at room temperature with n-heptane until the active substance precipitated. The residue was filtered off and dried at room temperature. It was investigated by X-ray diffractometry and corresponded to the title compound in the modification II.
= BHC 05 1117-Foreign countries Example 2.3 About 200 mg of 5-chloro-N-({(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-pheny1]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were dissolved hot in about 40 ml of I -pentanol. The solution was filtered and divided in half. One half was treated with n-heptane until the active substance precipitated. The residue was filtered off and dried at room temperature. It was investigated by X-ray diffractometry and corresponded to the title compound in the modification II.
Example 2.4 About 200 mg of 5-chloro-N-({(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were dissolved hot in about 40 ml of 1,4-dioxane. The solution was filtered and divided in half. One half was stored at 50 C in a drying oven until the solvent had evaporated. The residue was investigated by X-ray diffractometry and corresponded to the title compound in the modification 11.
Example 2.5 About 50 mg of 5-chloro-N-M5S)-2-oxo-344-(3-oxo-4-morpholiny1)-phenyl]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the amorphous form, prepared by fusing on a Kofler heating bench at about 240 C and subsequent shock cooling to room temperature, were suspended in about 2 ml of ethanol and stirred at 25 C for 0.5 h. The crystallizate was isolated and dried. The residue was investigated by X-ray diffractometry and corresponded to the title compound in the modification II.
Example 2.6 About 100 mg of 5-chloro-N-({(55)-2-oxo-3-[4-(3-oxo-4-morpholiny1)-phenyl]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were dissolved hot in about 50 ml of acetone. The solution was filtered and treated with n-heptane in an ice bath until the active substance precipitated. The residue was filtered off and dried at room temperature. It was investigated by X-ray diffractometry and corresponded to the title compound in the modification II.
Example 3: Preparation of 5-chloro-N-W5S)-2-oxo-3-1443-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-y1I-methyl)-2-thiophenecarboxamide in the modification III
About 120 mg of 5-chloro-N-({(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-pheny1]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were dissolved hot in about 50 ml of acetone. The solution was filtered, treated with about 50 ml of water and allowed to stand at room temperature until the solvent had evaporated. The residue was investigated thermoanalytically and BHC 05 1 I 17-Foreign countries corresponded to the title compound in the modification III.
Example 4: Preparation of the hydrate of 5-chloro-N-M5S)-2-oxo-3-14-(3-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide About 400 mg of 5-chloro-N-( {(5S)-2-oxo-3-[4-(3-oxo-4-morpholiny1)-pheny1]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were dissolved hot in about 60 ml of ethanol:water (1:1) and filtered. A part of the solution was stored in a freezer at a temperature of approximately ¨20 C until the solvent had evaporated. The residue corresponded to the hydrate of the title compound.
Example 5: Preparation of the NMP solvate of 5-chloro-N-({(5S)-2-oxo-3-14-(3-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide About 3.5 g of 5-chloro-N-(1(5,9-2-oxo-344-(3-oxo-4-morpholiny1)-phenyl]-1,3-oxazolidin-5-y11-methyl)-2-thiophenecarboxamide in the modification I were suspended in 10 ml of 1-methy1-2-pyrrolidone and stirred at room temperature. After a few hours, about 20 ml of NMP were additionally added. After two days, the suspension was filtered off with suction and the residue was dried at room temperature. The residue was investigated thermoanalytically and corresponded to the NMP solvate of the title compound having an NMP content of 18.5 percent by weight.
Example 6: Preparation of the inclusion compound with THF of 5-chloro-N-(1(5S)-2-oxo-3-14-(3-oxo-4-morpholiny1)-pheny11-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide About 400 mg of 5-chloro-N-({(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-pheny1]-1,3-oxazolidin-5-y1l-methy1)-2-thiophenecarboxamide in the modification I were dissolved hot in about 50 ml of tetrahydrofuran and filtered. A part of the solution was stored at room temperature until the solvent had evaporated. The residue was investigated thermoanalytically and corresponded to the inclusion compound with THF of the title compound.
Tab. 1: Differential scanning calorimetry and thermogravimetry Modifi- Modifi- Modifi- Hydrate NMP ESV
cation I cation II cation III solvate toluene Melting point [ C] 230 203 Transition point [ C] ca. 192 ca. 127 Mass loss [% by wt.] 0.1 0.1 <0.5 ca. 4 18.5 5-7 BHC 05 1117-Foreign countries , Tab. 2: X-ray diffractometry iReflections Modifi- Modifi- Modifi- Hydrate NMP ESV
with cation I cation II cation 111 [2 theta]
solvate THF
[2 theta] [2 theta] [2 theta] [2 theta] [2 theta]
8.9 12.8 11.7 3.6 4.8 9.0 12.0 17.7 16.5 14.3 5.8 12.0 14.3 18.1 17.5 16.4 7.3 14.3 16.5 18.4 19.1 16.6 10.9 14.7 17.4 19.0 19.6 17.5 14.5 16.5 18.1 19.9 19.8 19.3 15.2 16.8 19.5 20.8 23.1 19.6 15.7 17.5 19.9 21.6 23.2 19.9 16.0 19.6 21.7 22.1 23.8 20.2 17.6 19.9 22.5 22.9 24.3 21.7 17.9 21.7 23.4 24.1 28.1 22.5 20.0 22.5 24.1 26.1 28.2 24.2 20.6 23.4 24.5 26.4 31.2 25.6 21.3 24.5 24.7 26.6 25.8 21.8 24.7 25.6 27.2 28.8 22.3 25.2 26.4 27.5 29.5 22.7 25.6 26.7 28.8 31.8 23.1 26.4 30.0 29.8 32.7 23.3 26.7 30.1 31.0 23.5 28.7 31.8 31.6 24.0 30.1 32.9 24.7 31.0 24.9 31.8 25.2 26.0 26.5 26.9 28.0 28.8 29.2 29.5 29.8 BHC 05 1 117-Foreign countries Tab. 3: IR spectroscopy Peak maxima Modification Modification Modification Hydrate NMP
II II III [cm-I] solvate [cm-1] [cm-1 [cm-1] [cm4]
BHC 05 1117-Foreign coucnktriOes2624310 2008-04-01 Peak maxima Modification Modification Modification Hydrate NMP
II II III [cm-11 solvate [aril [cm-'1 [cm-11 [cm'l I
Tab. 4: Raman spectroscopy Peak maxima Modifi- Modifi- Modifi- Hydrate NMP
cation I cation II cation III [crn1 solvate [cm} [cm] [cm-1] [cm-l]
= BHC 05 1 117-Foreign countries Peak maxima Modifi- Modifi- Modifi- Hydrate NMP
cation I cation 11 cation III [cm']
solvate [cm-I] [cm] [cm-1 [cm-I]
BHC 05 1 117-Foreign countries Tab. 5: FIR spectroscopy Peak maxima Modifi- Modifi- Hydrate NMP solvate cation I cation II [cm'] [cm']
[cm1] [cm-l]
. BHC 05 1117-Foreign countries Tab. 6: NIR spectroscopy Peak maxima Modifi- Modifi- Modifi- Hydrate NMP
cation 1 cation I cation I
[cm-1 solvate [cm'} [cm'] [cm-1 [cm-1]
Example 7: Preparation of 5-chloro-N-(1(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-phenyll-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in amorphous form Example 7.1 About 50 mg of 5-chloro-N-(1(55)-2-oxo-344-(3-oxo-4-morpholiny1)-phenyl]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification 1 were fused on a Kofler heating bench at about 240 C and subsequently brought to room temperature by shock cooling. The active substance was investigated by X-ray diffractometry and was present in the amorphous form.
BHC 05 1117-Foreign countries Example 7.2 About 3 g of 5-chloro-N-({(5S)-2-oxo-344-(3-oxo-4-morpholiny1)-phenyl]-1,3-oxazolidin-5-yll-methyl)-2-thiophenecarboxamide in the modification I were fused in a drying oven at about 250 C
and subsequently brought to room temperature by shock cooling. The active compound was investigated by X-ray diffractometry and was present in the amorphous form.
Tab. 7: Differential scanning calorimetry and thermogravimetry (amorphous form) Glass transition temperature: about 83 C
Tab. 8: Spectroscopy (amorphous form) Peak maxima IR Raman FIR NIR
[cm-1] [cm-1] [cm-1] [cm-1]
BHC 05 1 117-Foreign countries CA 02624310 2008-04-01 Peak maxima IR Raman FIR NIR
[cm-11 [cm -11 [cm-1] [cm-1]
Claims (5)
1. A compound of the formula (I) in the modification II form.
2. A compound of the formula (I) in the modification II, wherein the compound of the formula (I) in the modification II shows peak maxima in the NIR spectra at 4086, 4228, 4418, 4457, 4634, 4905, 5846, 5911, 6026, 6081 and 6582 cm-1.
3. A medicament comprising the compound of claim 1 or 2, an inert, nontoxic, pharmaceutically suitable excipient.
4. Process for the preparation of a compound of the formula (I) in the modification II which in the NIR spectrogram has peak maxima at 4086, 4228, 4418, 4457, 4634, 4905, 5846, 5911, 6026, 6081 and 6582, comprising:
dissolving the compound of formula (I) in the modification I which in the NIR
spectrogram has peak maxima at 4082, 4142, 4170, 4228, 4299, 4376, 4429, 4479, 4633, 4791, 4877, 4907, 5081, 5760, 5885, 6002, 6441, 6564, 8473 and 8833, in methanol, ethanol, n-propanol, isopropanol, n-butanol, sec-butanol, isobutanol, 1-pentanol, acetone, n-pentane, cyclopentane, n-hexane, tetrahydrofuran, acetonitrile, ethyl acetate, or 1,4-dioxane, or a mixture thereof, or a mixture thereof with water at a temperature between 0°C and 80°C, and precipitating the compound by addition of n-heptane, cyclohexane or toluene.
5. Process for preparation of a compound of formula (I) in the modification II which in the NIR spectrogram has peak maxima at 4086, 4228, 4418, 4457, 4634, 4905, 5846, 5911, 6026, 6081 and 6582, the compound of the formula (I) in the amorphous form comprising:
suspending in n-heptane, cyclohexane or toluene, and stirring or shaking the suspension until quantitative conversion to the modification II.
in the modification II which in the NIR spectrogram has peak maxima at 4086, 4228, 4418, 4457, 4634, 4905, 5846, 5911, 6026, 6081 and 6582, comprising:
dissolving the compound of formula (I) in the modification I which in the NIR
spectrogram has peak maxima at 4082, 4142, 4170, 4228, 4299, 4376, 4429, 4479, 4633, 4791, 4877, 4907, 5081, 5760, 5885, 6002, 6441, 6564, 8473 and 8833, in methanol, ethanol, n-propanol, isopropanol, n-butanol, sec-butanol, isobutanol, 1-pentanol, acetone, n-pentane, cyclopentane, n-hexane, tetrahydrofuran, acetonitrile, ethyl acetate, or 1,4-dioxane, or a mixture thereof, or a mixture thereof with water at a temperature between 0°C and 80°C, and precipitating the compound by addition of n-heptane, cyclohexane or toluene.
dissolving the compound of formula (I) in the modification I which in the NIR
spectrogram has peak maxima at 4082, 4142, 4170, 4228, 4299, 4376, 4429, 4479, 4633, 4791, 4877, 4907, 5081, 5760, 5885, 6002, 6441, 6564, 8473 and 8833, in methanol, ethanol, n-propanol, isopropanol, n-butanol, sec-butanol, isobutanol, 1-pentanol, acetone, n-pentane, cyclopentane, n-hexane, tetrahydrofuran, acetonitrile, ethyl acetate, or 1,4-dioxane, or a mixture thereof, or a mixture thereof with water at a temperature between 0°C and 80°C, and precipitating the compound by addition of n-heptane, cyclohexane or toluene.
5. Process for preparation of a compound of formula (I) in the modification II which in the NIR spectrogram has peak maxima at 4086, 4228, 4418, 4457, 4634, 4905, 5846, 5911, 6026, 6081 and 6582, the compound of the formula (I) in the amorphous form comprising:
suspending in n-heptane, cyclohexane or toluene, and stirring or shaking the suspension until quantitative conversion to the modification II.
in the modification II which in the NIR spectrogram has peak maxima at 4086, 4228, 4418, 4457, 4634, 4905, 5846, 5911, 6026, 6081 and 6582, comprising:
dissolving the compound of formula (I) in the modification I which in the NIR
spectrogram has peak maxima at 4082, 4142, 4170, 4228, 4299, 4376, 4429, 4479, 4633, 4791, 4877, 4907, 5081, 5760, 5885, 6002, 6441, 6564, 8473 and 8833, in methanol, ethanol, n-propanol, isopropanol, n-butanol, sec-butanol, isobutanol, 1-pentanol, acetone, n-pentane, cyclopentane, n-hexane, tetrahydrofuran, acetonitrile, ethyl acetate, or 1,4-dioxane, or a mixture thereof, or a mixture thereof with water at a temperature between 0°C and 80°C, and precipitating the compound by addition of n-heptane, cyclohexane or toluene.
5. Process for preparation of a compound of formula (I) in the modification II which in the NIR spectrogram has peak maxima at 4086, 4228, 4418, 4457, 4634, 4905, 5846, 5911, 6026, 6081 and 6582, the compound of the formula (I) in the amorphous form comprising:
suspending in n-heptane, cyclohexane or toluene, and stirring or shaking the suspension until quantitative conversion to the modification II.
suspending in n-heptane, cyclohexane or toluene, and stirring or shaking the suspension until quantitative conversion to the modification II.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2823159A CA2823159C (en) | 2005-10-04 | 2006-09-22 | Polymorphic form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005047563A DE102005047563A1 (en) | 2005-10-04 | 2005-10-04 | New modification of specific substituted thiophene carboxamide, useful for prevention and treatment of thrombo-embolic disease, has higher solubility than known modifications |
DE102005047563.9 | 2005-10-04 | ||
DE102005047564A DE102005047564A1 (en) | 2005-10-04 | 2005-10-04 | New forms of specific substituted thiophene carboxamide (rivaroxaban), useful for prevention and treatment of thromboembolic disease, have higher solubility than known modifications |
DE102005047564.7 | 2005-10-04 | ||
PCT/EP2006/009202 WO2007039132A1 (en) | 2005-10-04 | 2006-09-22 | Novel polymorphous form and the amorphous form of 5-chloro-n-({ (5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2823159A Division CA2823159C (en) | 2005-10-04 | 2006-09-22 | Polymorphic form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2624310A1 CA2624310A1 (en) | 2007-04-12 |
CA2624310C true CA2624310C (en) | 2014-01-07 |
Family
ID=37691766
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2624310A Active CA2624310C (en) | 2005-10-04 | 2006-09-22 | Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide |
CA2823159A Active CA2823159C (en) | 2005-10-04 | 2006-09-22 | Polymorphic form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2823159A Active CA2823159C (en) | 2005-10-04 | 2006-09-22 | Polymorphic form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide |
Country Status (23)
Country | Link |
---|---|
US (1) | US8188270B2 (en) |
EP (1) | EP1934208B1 (en) |
JP (1) | JP5416408B2 (en) |
KR (1) | KR101364400B1 (en) |
AT (1) | ATE502937T1 (en) |
AU (1) | AU2006299126B2 (en) |
BR (1) | BRPI0616801B8 (en) |
CA (2) | CA2624310C (en) |
CR (1) | CR9863A (en) |
DE (1) | DE502006009169D1 (en) |
DK (1) | DK1934208T3 (en) |
EC (1) | ECSP088341A (en) |
HK (1) | HK1125103A1 (en) |
IL (1) | IL190204A (en) |
MY (1) | MY145616A (en) |
NO (1) | NO341632B1 (en) |
NZ (1) | NZ567092A (en) |
PL (1) | PL1934208T3 (en) |
PT (1) | PT1934208E (en) |
RU (2) | RU2429236C2 (en) |
SG (1) | SG166126A1 (en) |
SV (1) | SV2009002858A (en) |
WO (1) | WO2007039132A1 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19962924A1 (en) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituted oxazolidinones and their use |
DE10129725A1 (en) | 2001-06-20 | 2003-01-02 | Bayer Ag | Combination therapy of substituted oxazolidinones |
DE10300111A1 (en) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide |
DE10355461A1 (en) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases |
EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
DE102005045518A1 (en) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa |
DE502006009169D1 (en) | 2005-10-04 | 2011-05-05 | Bayer Schering Pharma Ag | NEUE POLYMORPHE FORM VON 5-CHLOR-N-(ä ( 5S )-2-0X0-3-Ä4-( 3-OXO-4-MORPHOLINYL)-PHENYLÜ-1,3-OXAZOLIDIN-5-YLü -METHYL)-2-THIOPHENCARBOXAMID |
DE102005047561A1 (en) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance |
DE102007028318A1 (en) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Oxazolidinone for the treatment and prophylaxis of sepsis |
US7985750B2 (en) * | 2007-08-14 | 2011-07-26 | Concert Pharmaceuticals, Inc. | Substituted oxazolidinone derivatives |
EP2220079A2 (en) * | 2007-11-15 | 2010-08-25 | Boehringer Ingelheim International GmbH | Substituted amides, manufacturing and use thereof as medicaments |
DE102008028071A1 (en) * | 2008-06-12 | 2009-12-17 | Bayer Schering Pharma Aktiengesellschaft | New cocrystal compound of rivaroxaban and malonic acid |
MX2011000277A (en) | 2008-07-08 | 2011-06-22 | Ratiopharm Gmbh | Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2 -oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-met hyl)-2-thiophencarboxamid. |
US20100168111A1 (en) * | 2008-12-31 | 2010-07-01 | Apotex Pharmachem Inc. | Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide |
US7816355B1 (en) * | 2009-04-28 | 2010-10-19 | Apotex Pharmachem Inc | Processes for the preparation of rivaroxaban and intermediates thereof |
EP2266541A1 (en) | 2009-06-18 | 2010-12-29 | Krka Tovarna Zdravil, D.D., Novo Mesto | Solid pharmaceutical composition comprising rivaroxaban |
HUE031177T2 (en) | 2009-06-18 | 2017-07-28 | Krka Tovarna Zdravil D D Novo Mesto | Solid pharmaceutical composition comprising rivaroxaban |
PL2459555T3 (en) | 2009-07-31 | 2022-03-28 | Krka, D.D., Novo Mesto | Processes for crystallization of rivaroxaban |
EP2308472A1 (en) | 2009-10-06 | 2011-04-13 | ratiopharm GmbH | Pharmaceutical compositions comprising rivaroxaban |
WO2011042156A1 (en) | 2009-10-06 | 2011-04-14 | Ratiopharm Gmbh | Pharmaceutical compositions comprising rivaroxaban |
EP2404920A1 (en) | 2010-07-06 | 2012-01-11 | Sandoz AG | Crystalline form of Rivaroxaban dihydrate |
US20130253187A1 (en) | 2010-09-14 | 2013-09-26 | Medichem, S.A. | Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative |
AT511045A1 (en) | 2011-01-28 | 2012-08-15 | Blum Gmbh Julius | FURNITURE WITH A TORQUE TRANSMISSION |
WO2013098833A2 (en) | 2011-09-08 | 2013-07-04 | Cadila Healthcare Limited | Processes and intermediates for preparing rivaroxaban |
EP2573084A1 (en) | 2011-09-22 | 2013-03-27 | Enantia, S.L. | Novel crystalline forms of rivaroxaban and processes for their preparation |
HU230734B1 (en) | 2011-10-10 | 2017-12-28 | EGIS Gyógyszergyár Nyrt | Cocrystals of rivaroxaban for producing pharmaceutical compositions |
WO2014016842A1 (en) * | 2012-07-23 | 2014-01-30 | Symed Labs Limited | Amorphous coprecipitates of rivaroxaban |
ES2647607T3 (en) * | 2012-12-21 | 2017-12-22 | Farma Grs, D.O.O. | Procedure for the preparation of rivaroxaban |
US9359341B2 (en) | 2012-12-26 | 2016-06-07 | Wanbury Ltd. | Aldehyde derivative of substitute oxazolidinones |
PT2895176T (en) | 2012-12-26 | 2017-01-27 | Wanbury Ltd | Rivaroxaban intermediate and preparation thereof |
IN2014CH00290A (en) | 2014-01-23 | 2015-08-14 | Symed Labs Ltd | |
WO2015176677A1 (en) * | 2014-05-22 | 2015-11-26 | Sunshine Lake Pharma Co., Ltd. | Crystalline forms and amorphism of oxazolidinone compound |
EA034656B1 (en) * | 2014-10-22 | 2020-03-03 | Закляды Фармацеутычне Польфарма С.А | Process for preparing a polymorph of rivaroxaban |
RU2020103395A (en) * | 2020-01-28 | 2021-07-28 | Закрытое Акционерное Общество "Алмаз Фарм" | L-, U-modification of 5-chloro-N - ({5S) -2-oxo-3- [4-3-oxo-4-morpholinyl) -phenyl] -1,3-oxazolidin-5-yl} -methyl ) -2-thiophenecarboxamide, solvate with dimethyl sulfoxide, methods for their preparation, pharmaceutical compositions based on them, inhibiting factor Xa |
GB202102575D0 (en) | 2021-02-23 | 2021-04-07 | Teva Pharmaceutical Industries Ltd | Fixed-dose pharmaceutical compositions |
GR1010231B (en) | 2021-03-24 | 2022-05-10 | Φαρματεν Α.Β.Ε.Ε., | Pharmaceutical composition comprising rivaroxaban and method of preparation thereof |
EP4201933A1 (en) | 2021-12-23 | 2023-06-28 | Zaklady Farmaceutyczne Polpharma S.A. | Crystallisation process for rivaroxaban |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2811555A (en) | 1955-05-02 | 1957-10-29 | Eastman Kodak Co | Reduction of 2-nitroso-5-diethylaminotoluene |
US3279880A (en) | 1965-07-12 | 1966-10-18 | Eastman Kodak Co | Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones |
LU80081A1 (en) | 1977-08-26 | 1979-05-15 | Delalande Sa | NEW HYDROXYMETHYL-5 OXAZOLIDINONES-2, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION |
US4128654A (en) | 1978-02-10 | 1978-12-05 | E. I. Du Pont De Nemours And Company | 5-Halomethyl-3-phenyl-2-oxazolidinones |
US4500519A (en) | 1978-11-06 | 1985-02-19 | Choay S.A. | Mucopolysaccharides having biological properties, preparation and method of use |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
HU190072B (en) | 1983-03-11 | 1986-08-28 | Biogal Gyogyszergyar,Hu | Process for production of medical preparatives with sinergetic influence |
NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
ES8506659A1 (en) | 1983-06-07 | 1985-08-01 | Du Pont | Aminomethyl oxooxazolidinyl benzene derivatives useful as antibacterial agents. |
US4977173A (en) | 1987-10-21 | 1990-12-11 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
CA1317594C (en) | 1987-10-21 | 1993-05-11 | Chung-Ho Park | Aminomethyloxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
DE3822650A1 (en) | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
US4948801A (en) | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US5254577A (en) | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
JP3176626B2 (en) | 1991-11-01 | 2001-06-18 | ファルマシア・アンド・アップジョン・カンパニー | Substituted aryl- and heteroarylphenyloxazolidinones useful as antimicrobial agents |
SK283420B6 (en) | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Oxazolidinones containing a substituted diazine moiety and their use as antimicrobials |
US5349045A (en) | 1993-01-26 | 1994-09-20 | United States Surgical Corporation | Polymer derived from cyclic amide and medical devices manufactured therefrom |
DK0623615T3 (en) | 1993-05-01 | 1999-12-13 | Merck Patent Gmbh | Adhesion receptor antagonists |
US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
DE4332384A1 (en) | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhesion receptor antagonists III |
DK0807112T3 (en) | 1995-02-03 | 2001-12-17 | Upjohn Co | Antimicrobial heteroaromatic ring-substituted phenyloxazolidinone |
HRP960159A2 (en) | 1995-04-21 | 1997-08-31 | Bayer Ag | Benzocyclopentane oxazolidinones containing heteroatoms |
DE19524765A1 (en) | 1995-07-07 | 1997-01-09 | Boehringer Mannheim Gmbh | New oxazolidinone derivatives, processes for their preparation and medicaments containing these compounds |
HUP9901979A3 (en) | 1995-09-01 | 2000-03-28 | Upjohn Co | Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings and pharmaceutical compositions containing the same |
WO1997010223A1 (en) | 1995-09-15 | 1997-03-20 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone n-oxides |
DE19601264A1 (en) | 1996-01-16 | 1997-07-17 | Bayer Ag | Pyrido-annellated thienyl and furanyl oxazolidinones |
DE19604223A1 (en) | 1996-02-06 | 1997-08-07 | Bayer Ag | New substituted oxazolidinones |
HRP970049A2 (en) | 1996-02-06 | 1998-04-30 | Bayer Ag | New heteroaryl oxazolidinones |
GB9614238D0 (en) | 1996-07-06 | 1996-09-04 | Zeneca Ltd | Chemical compounds |
CZ299162B6 (en) | 1996-07-15 | 2008-05-07 | Sankyo Company, Limited | Pharmaceutical composition and kit |
US5935724A (en) | 1997-04-04 | 1999-08-10 | Wilson Greatbatch Ltd. | Electrochemical cell having multiplate electrodes with differing discharge rate regions |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
NZ501412A (en) | 1997-05-30 | 2001-11-30 | Upjohn Co | Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
EP0994874A1 (en) | 1997-07-11 | 2000-04-26 | PHARMACIA & UPJOHN COMPANY | Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents |
DE19730847A1 (en) | 1997-07-18 | 1999-01-28 | Bayer Ag | Tricyclically substituted oxazolidinones |
GB9715894D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic derivatives |
DE19747261A1 (en) | 1997-10-25 | 1999-04-29 | Bayer Ag | Single-chamber osmotic pharmaceutical release system |
CA2303959A1 (en) | 1997-11-12 | 1999-05-20 | Pharmacia & Upjohn Company | Oxazolidinone derivatives and pharmaceutical compositions |
US6083967A (en) | 1997-12-05 | 2000-07-04 | Pharmacia & Upjohn Company | S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones |
DE19755268A1 (en) | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidine derivatives |
AU764184B2 (en) | 1998-01-23 | 2003-08-14 | Pharmacia & Upjohn Company | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
ZA99607B (en) | 1998-01-27 | 1999-07-27 | Rhone Poulenc Rorer Pharma | Substituted oxoazaheterocyclyl factor xa inhibitors. |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
HUP0101958A3 (en) | 1998-05-18 | 2003-07-28 | Upjohn Co | Enhancement oxazolidinone antibacterial agents activity by using arginine derivatives |
DE19842753A1 (en) | 1998-09-18 | 2000-03-23 | Bayer Ag | Multiple-unit retard oral dosage formulation having controlled release independent of agitation and food effect, containing particles of combination of drug and hydroxypropyl cellulose |
US6413981B1 (en) | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
PE20010851A1 (en) | 1999-12-14 | 2001-08-17 | Upjohn Co | BENZOIC ACID ESTERS OF OXAZOLIDINONES HAVING A HYDROXYACETILPIPERAZINE SUBSTITUENT |
AU782078B2 (en) | 1999-12-21 | 2005-06-30 | Pharmacia & Upjohn Company | Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
DE19962924A1 (en) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituted oxazolidinones and their use |
AU2225901A (en) | 1999-12-28 | 2001-07-09 | Ajinomoto Co., Inc. | Aspartame derivative crystals |
DE10105989A1 (en) | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituted oxazolidinones and their use |
DE10110438A1 (en) | 2001-03-05 | 2002-09-19 | Bayer Ag | Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and their use |
DE10110747A1 (en) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use |
DE10110754A1 (en) | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use |
DE10115922A1 (en) | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclically substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use |
DE10115945A1 (en) | 2001-03-30 | 2002-10-02 | Bayer Ag | Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and their use |
DE10129725A1 (en) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Combination therapy of substituted oxazolidinones |
DE10134481A1 (en) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use |
DE10152460A1 (en) | 2001-10-24 | 2003-05-08 | Bayer Ag | stents |
DE10238113A1 (en) | 2001-12-11 | 2003-06-18 | Bayer Ag | New 2-substituted methylthio-dicyanopyridine derivatives, useful for treating or preventing e.g. cardiovascular disease and inflammation, are adenosine A1 receptor agonists |
US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
US20040024660A1 (en) | 2002-08-05 | 2004-02-05 | General Electric Company | System and method for providing asset management and tracking capabilities |
DE10300111A1 (en) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide |
DE10355461A1 (en) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases |
DE102004002044A1 (en) * | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | manufacturing |
DE102004062475A1 (en) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Solid, orally administrable, modified release pharmaceutical dosage forms |
EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
DE102005045518A1 (en) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa |
DE102005047558A1 (en) | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Combination therapy of substituted oxazolidinones for the prophylaxis and treatment of cerebral circulatory disorders |
DE502006009169D1 (en) | 2005-10-04 | 2011-05-05 | Bayer Schering Pharma Ag | NEUE POLYMORPHE FORM VON 5-CHLOR-N-(ä ( 5S )-2-0X0-3-Ä4-( 3-OXO-4-MORPHOLINYL)-PHENYLÜ-1,3-OXAZOLIDIN-5-YLü -METHYL)-2-THIOPHENCARBOXAMID |
DE102005047561A1 (en) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance |
DE102005048824A1 (en) | 2005-10-10 | 2007-04-12 | Bayer Healthcare Ag | Treatment and prophylaxis of microangiopathies |
-
2006
- 2006-09-22 DE DE502006009169T patent/DE502006009169D1/en active Active
- 2006-09-22 SG SG201007274-2A patent/SG166126A1/en unknown
- 2006-09-22 CA CA2624310A patent/CA2624310C/en active Active
- 2006-09-22 DK DK06792210.4T patent/DK1934208T3/en active
- 2006-09-22 US US12/089,095 patent/US8188270B2/en active Active
- 2006-09-22 EP EP06792210A patent/EP1934208B1/en active Active
- 2006-09-22 RU RU2008116834/04A patent/RU2429236C2/en active
- 2006-09-22 NZ NZ567092A patent/NZ567092A/en unknown
- 2006-09-22 JP JP2008533895A patent/JP5416408B2/en active Active
- 2006-09-22 KR KR1020087008058A patent/KR101364400B1/en active IP Right Grant
- 2006-09-22 PL PL06792210T patent/PL1934208T3/en unknown
- 2006-09-22 AT AT06792210T patent/ATE502937T1/en active
- 2006-09-22 BR BRPI0616801A patent/BRPI0616801B8/en active IP Right Grant
- 2006-09-22 WO PCT/EP2006/009202 patent/WO2007039132A1/en active Application Filing
- 2006-09-22 RU RU2011115874/04A patent/RU2578602C2/en active
- 2006-09-22 AU AU2006299126A patent/AU2006299126B2/en active Active
- 2006-09-22 PT PT06792210T patent/PT1934208E/en unknown
- 2006-09-22 CA CA2823159A patent/CA2823159C/en active Active
- 2006-09-22 MY MYPI20080967A patent/MY145616A/en unknown
-
2008
- 2008-03-17 IL IL190204A patent/IL190204A/en active IP Right Grant
- 2008-04-02 SV SV2008002858A patent/SV2009002858A/en unknown
- 2008-04-02 EC EC2008008341A patent/ECSP088341A/en unknown
- 2008-04-03 CR CR9863A patent/CR9863A/en unknown
- 2008-04-30 NO NO20082059A patent/NO341632B1/en unknown
-
2009
- 2009-03-31 HK HK09103051.1A patent/HK1125103A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2624310C (en) | Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide | |
US8466280B2 (en) | Co-crystal compound of rivaroxaban and malonic acid | |
ES2362009T3 (en) | NEW POLYMORPHIC FORM OF 5-CHLORINE-N ({(5S) -2-OXO-3- [4- (3-OXO-4-MORFOLINIL) -FENIL] -1,3-OXAZOLIDIN-5-IL} METHYL) - 2-THIOPHENOCARBOXAMIDE. | |
KR20160078980A (en) | Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid | |
WO2009007026A1 (en) | Aminoacyl prodrugs | |
US20100041646A1 (en) | Phenylene-Bis-Oxazolidine Derivatives and Their Use as Anticoagulants | |
DE102005047563A1 (en) | New modification of specific substituted thiophene carboxamide, useful for prevention and treatment of thrombo-embolic disease, has higher solubility than known modifications | |
JP2009538847A (en) | Substituted heterocycles and their use | |
US20110288174A1 (en) | Monohydrate of 4-(phenyl)ethyl]-amino}methyl)benzoic acid | |
US20120010292A1 (en) | Modification i of 4-(phenyl)ethyl]-amino}methyl)benzoic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |